Drugs / GAP-486
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT00137332 | Nov 2005 → Oct 2006 | cardiac rhythm disease | Wyeth is now a wholly owned subsidiary of Pfizer | Terminated | No outcome recorded |
| Phase 2 | NCT00137293 | Nov 2005 → Oct 2006 | cardiac rhythm disease | Wyeth is now a wholly owned subsidiary of Pfizer | Terminated | No outcome recorded |
| Phase 2 | NCT00124891 | Jun 2005 → Nov 2006 | cardiac rhythm disease | Wyeth is now a wholly owned subsidiary of Pfizer | Terminated | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | GAP-486 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00137332 ↗ |
| Known as | ZP-123 | “GAP-486 (ZP-123)” NCT00137332 ↗1“GAP-486 (ZP-123)” NCT00137293 ↗ |